The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Speakers' Bureau - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Novartis
Patents, Royalties, Other Intellectual Property - WeHI
Travel, Accommodations, Expenses - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.
 
Heikki Joensuu
Employment - Orion
Leadership - Sartar Therapeutics
Stock and Other Ownership Interests - Faron Pharmaceuticals; Orion
Consulting or Advisory Role - Neutron Therapeutics
Patents, Royalties, Other Intellectual Property - Sartar Therapeutics
 
Mikael Eriksson
Honoraria - Bayer; Bayer
Consulting or Advisory Role - Isofol Medical; Isofol Medical
Research Funding - Novartis; Novartis
 
Kirsten Sundby Hall
No Relationships to Disclose
 
Annette Reichardt
Honoraria - Amgen (I); Bayer (I); Lilly (I); Novartis (I); Pfizer (I); PharmaMar (I)
Consulting or Advisory Role - Bayer (I); Clinigen Group (I); Deciphera (I); Lilly (I); Novartis (I); Pfizer (I); PharmaMar (I); Roche (I)
Research Funding - Novartis (Inst)
 
Barbara Hermes
Research Funding - AstraZeneca (Inst); Bayer Health (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); PharmaMar (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Lilly; PharmaMar
 
Jochen Schuette
No Relationships to Disclose
 
Silke Cameron
No Relationships to Disclose
 
Peter Hohenberger
Honoraria - Boehringer Ingelheim; Lilly; Pfizer; Roche
Consulting or Advisory Role - Lilly; Nanobiotix; Pfizer
Research Funding - Novartis; Siemens Healthcare Diagnostics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Philipp Jost
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - IKF Klinische Krebsforschung
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; MCI group; Nordic Bioscience
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma
 
Lars H Lindner
Stock and Other Ownership Interests - Thermosome
Honoraria - Lilly; PharmaMar
Consulting or Advisory Role - EL Medconsult; Jazz Pharmaceuticals; Lilly; Roche
Research Funding - Sennewald GmbH (Inst)
Patents, Royalties, Other Intellectual Property - Thermosensitive liposomes based on DPPG2
Travel, Accommodations, Expenses - Lilly; PharmaMar
 
Sebastian Bauer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Bayer; Blueprint Medicines; Daiichi Sankyo; Deciphera; Exelixis; Janssen-Cilag; Janssen-Cilag; Lilly; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Eva Wardelmann
Honoraria - Bayer; Bristol-Myers Squibb; Lilly; Nanobiotix; Novartis; Roche
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; New Oncology; Roche
Research Funding - Nanobiotix; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Nanobiotix; Roche
 
Bengt E. Nilsson
No Relationships to Disclose
 
Raija S. Kallio
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Nordic Drugs; Roche; Sanofi; SERVIER
 
Panu Jaakkola
Consulting or Advisory Role - Ipsen; MSD
 
Jouni Junnila
Other Relationship - 4Pharma
 
Thor Alvegard
No Relationships to Disclose
 
Peter Reichardt
Honoraria - Amgen; Bayer; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Clinigen Group; Deciphera; Lilly; Novartis; Pfizer; PharmaMar; Roche
Research Funding - Novartis (Inst)